Skip to main content
. 2016 Jun 17;7(30):47319–47331. doi: 10.18632/oncotarget.10118

Figure 8. Subgroup analysis for the two combination treatments on the low-to-intermediate-risk (WBC ≤ 10 × 109/L) and high-risk (WBC > 10 × 109/L) patients.

Figure 8

HR = hazard ratio. I − V = inverse variance. D + L = DerSimonan and Laird.